Domainex Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Domainex's estimated annual revenue is currently $23.1M per year.(i)
  • Domainex's estimated revenue per employee is $155,000

Employee Data

  • Domainex has 149 Employees.(i)
  • Domainex grew their employee count by 6% last year.

Domainex's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
EVP Medicines Research & Strategic AlliancesReveal Email/Phone
3
Associate Director - Head BiologyReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
Chief Operating OfficerReveal Email/Phone
6
Associate Director, Medicinal ChemistryReveal Email/Phone
7
Director Business DevelopmentReveal Email/Phone
8
Director Human Resources and FacilitiesReveal Email/Phone
9
Director ChemistryReveal Email/Phone
10
Facilities and Laboratory ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.5M29-12%N/AN/A
#2
$15.7M1015%N/AN/A
#3
$87.9M40525%$292MN/A
#4
$2.6M47016%$631.7MN/A
#5
$14.9M96-8%$81MN/A
#6
$44.8M2310%$132.9MN/A
#7
$7.6M49-37%N/AN/A
#8
$17.4M11212%N/AN/A
#9
$334.6M134911%£994.6MN/A
#10
$830.2M53568%N/AN/A
Add Company

What Is Domainex?

Domainex is a fully integrated drug discovery service company based near Cambridge, UK serving pharmaceutical, biotechnology, academic and patient foundations globally. Our expertise and commitment to providing high quality services has resulted in a strong success record in drug discovery, delivering an average one candidate drug every year for the past six years.\n\nDomainex’s highly experienced molecular, protein, structural and assay biologists plus medicinal, computational and analytical chemists can be leveraged through our CRO services. Domainex’s focus is on providing highly efficient and well considered scientific solutions to enable successful drug discovery programmes against a wide range of drug targets. \n\nDomainex offers a range of services including:\n• Medicinal chemistry (including SBDD)\n• FragmentBuilder (Domainex’s proprietary fragment screening platform)\n• Computational Chemistry (including LeadBuilder Domainex’s proprietary virtual screening platform)\n• Assay Development and Screening (biochemical, biophysical and cell assays)\n• iPSC and immune cell biology\n• Protein Production\n• CDH (Domainex’s proprietary technology which enables the rapid identification of stable, soluble protein domains)\n• Analytical chemistry\n• X-ray crystallography services\n\nWhether your project is at an early stage of drug discovery or has already identified chemical matter, our processes have been shown to result in a 30% time-saving compared to industry standards and use less resource, allowing prudent management of your own budget.

keywords:N/A

N/A

Total Funding

149

Number of Employees

$23.1M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Domainex News

2022-04-20 - Epigenetics Market Growth Factors Covid-19 Impact Analysis ...

Trending. Epigenetics Market Growth Factors Covid-19 Impact Analysis 2021-2030 | Domainex CellCentric Ltd. Chroma Therapeutics Ltd.

2022-04-19 - Drug Discovery Outsourcing Market See Huge Growth for New ...

Some of the Top companies Influencing in this Market include:Charles River , Domainex , EVOTEC, GenScript , GVK Biosciences , Laboratory...

2016-01-26 - Domainex and Cresset announce drug discovery services alliance

Domainex and Cresset announce drug discovery services alliance 26-01-2016 Domainex and Cresset alliance will provide customers with world-class laboratory-based and computational drug discovery services through a seamless combination of their respective capabilities in chemistry and biology. ...

2016-01-26 - Domainex and Cresset announce drug discovery services alliance

Domainex and Cresset announce drug discovery services alliance 26-01-2016 Domainex and Cresset alliance will provide customers with world-class laboratory-based and computational drug discovery services through a seamless combination of their respective capabilities in chemistry and biology. ...

2015-04-20 - Queen’s University Belfast & Domainex collaborate to advance novel lung cancer drug research

Queen’s University Belfast & Domainex collaborate to advance novel lung cancer drug research 20-04-2015 Dr Dan Longley’s research team at Queen’s University Belfast, and Domainex Ltd., specialists in drug discovery solutionsand translational research support; today announce the latest developm ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.6M1492%N/A
#2
$28.9M1493%$109M
#3
$15M149-10%N/A
#4
$36.1M1495%N/A
#5
$3.5M1507%N/A